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Sorafenib and everolimus combination in non-resectable high-grade 
osteosarcoma progressing after standard treatment: a non-randomized phase II 
clinical trial from the Italian Sarcoma Group. 
Abstract 
Background: Unresectable advanced/metastatic osteosarcoma represents an unmet medical need in which we 
demonstrated promising but short-lasting activity of sorafenib. We showed mTOR pathway is involved in 
sorafenib failure and represents a reasonable co-target to hit using everolimus. 
Methods: Patients>17 years affected by relapsed/unresectable osteosarcoma, progressing after standard 
treatments, received sorafenib 800 mg plus everolimus 5 mg daily until progression or unacceptable toxicity in a 
Simon two-stage study (NCT01804374). Primary endpoint was 6-month progression-free survival rate 6mPFS. 
Setting α=5%, β=10%, at least 37 patients were needed to test if 6mPFS  was ≤25%=P0 (9 patients) or ≥50%=P1 
(19 patients). Secondary endpoints were PFS, overall survival, RECIST 1.1 objective response rate (ORR), safety 
and their correlations with biomarkers. Survival endpoints were estimated by Kaplan-Meier method with 95% 
confidence intervals (CI). Tests were two-sided when indicated.  
Findings: Between June 2011 and June 2013, 38 patients were enrolled. 6mPFS was 45% (95%CI 28-61%, 17 
patients). Median PFS and overall survival were 5 (95%CI 2-7) and 11 (95%CI 8-15) months, respectively. We 
observed two (5%) partial responses (PR), two minor responses (5%), 20 (53%) stable diseases (SD) for an ORR 
of 10%. PR/SD lasted more than six months in eight (21%) patients (6, 6, 7, 8, 8, 8, 10+, 11). One patient 
interrupted the study to undergo lung metastasectomy after ten months of disease control. Treatment was feasible, 
but toxicity led to dose reductions and/or short interruptions in 25 (66%) patients and permanent discontinuation 
in two (5%) patients. P-ERK1/2 and P-RPS6 immunohistochemical expression positively correlated with primary 
and secondary endpoints. 
Interpretation: This combination showed activity as further-line treatment in advanced/unresectable 




was as expected. P-ERK1/2 and P-RPS6 expression may contribute to identify patients likely benefitting from 
this therapy. 
Funding: Italian Sarcoma Group 
 
Introduction. 
High-grade osteosarcoma (HG-OS) is a rare sarcoma affecting approximately 1150 new patients per 
year in the European Union.
1
 As of today, a multidisciplinary treatment encompassing 
chemotherapy and complete surgical removal of the tumor cures roughly 70% of the patients.
2
 The 
single most important predictive factor for cure remains the possibility to completely resect the 
tumor with adequate margins both in the localized
3
 and in the relapsed/metastatic setting.
4,5 
Unfortunately, the most active chemotherapy with high-dose methotrexate, doxorubicin, cisplatin, 
+/- ifosfamide (MAP/I) and mifamurtide,
2
 may eradicate micro-metastatic disease, but does not 
cure non-resectable disease. Several second- and further-line treatments have been tested6-12 
showing a marginal activity at most. The observed response rates were in the order of 3.1%11 to 
29%7-9 with a median progression-free survival (PFS) ranging from 1.411 to about 4 months.8,9  
The increased knowledge of oncogenic pathways involved in HG-OS pathogenesis along with the 
advent of target therapies, prompted the exploration of drugs hitting identified key-proteins. 
Consequently, small inhibitors as imatinib and monoclonal antibodies as trastuzumab), 
bevacizumab13 and anti-Insulin-like Growth Factor-1 Receptor (IGF-1R)
13,14
 have been tested 
without evidence of significant activity in advanced HG-OS. In this context, phospho-extracellular-
regulated kinase 1/2 (P-ERK1/2) were shown to be involved into HG-OS growth, survival, 
neoangiogenesis and metastatic potential
15,16
. Interestingly, sorafenib, a multikinase inhibitor of 
proven efficacy in renal, hepatic and thyroid cancers
17
, was demonstrated to abrogate growth and 
metastatization of a spectrum of osteosarcoma cell lines both in in vitro and in vivo models
15
. These 




or progressed after standard treatment and deemed unresectable
18
. In this scenario, sorafenib 
showed hints of antitumor activity in terms of response rate (14%), reduction of both metastases 
18
FDG-uptake and tumor density and, finally, improvement in pain control. Unfortunately, these 




Later, it was shown that Akt-mTOR pathway is involved into the mechanisms of resistance to 
sorafenib in HG-OS
19
. Indeed, while sorafenib abrogates mTORC1 complex activity, mTORC2 
complex, on the contrary, is activated leading to tumor progression. These results were consistent 
with several lines of evidences demonstrating that on one hand, inhibition of mTORC1 complex 
alone was ineffective
20
 and, on the other hand, inhibition of key tyrosine kinase receptors such as 
IGF-1R induces an increased activity of mTOR pathway by means of mTORC2 complex
13,21,22
. 
Interestingly, in preclinical models this mechanism of resistance was shown to be effectively 
overcome by the combination of sorafenib with the mTOR inhibitor everolimus
19
. In phase I/II 
trials this combination has been extensively studied in renal and hepatic cancers at several different 
doses
23-25 
showing that it is feasible. Given our former experience with sorafenib at full dose, we 
regarded sorafenib and everolimus at the daily dose of 800 and 5 mg, respectively, as the most 
appropriate dose to be explored in HG-OS. Finally, we hypothesized that in patients’ specimens the 
phosphorylation of down-stream key signaling proteins as P-ERK1/2 and phospho-ribosomal 
protein S6 (P-RPS6) targeted by sorafenib and everolimus, respectively, could be used to identify 
patients most likely to benefit from this combination. 
On these basis, we designed a phase II trial aiming to investigate the activity of the combination of 








Patients with not surgically amenable, histologically documented, locally advanced/metastatic HG-
OS having progressed after first- or second-line treatments for relapsing/metastatic disease were 
enrolled at 3 Italian Sarcoma Group centers. Eligibility criteria included progressive and measurable 
disease according to RECIST 1.1 (bone lesions allowed),
26
 18 year-old or greater, Eastern 
Cooperative Oncology Group (ECOG) performance status (PS) of 0/1, life expectancy ≥3 months, 
adequate organ and bone marrow function. Details on inclusion and exclusion criteria are available 
in appendix 1. 
 
Study Design and Treatment 
Patients were treated with sorafenib 400 mg twice daily and everolimus 5 mg daily given in an 
open-label fashion until progression, unacceptable toxicities or patient's refusal. Adverse events 
(AEs) were evaluated and graded according to Common Terminology Criteria for Adverse Event 
v4.03 (CTCAE). AEs management followed predefined rules (see supplementary material, online 
only). Each participating center Institutional Review Board and Independent Ethics Committee 
revised and approved all protocol documents. The study was conducted according to the 
Declaration of Helsinki and the International Conference on Harmonization of Good Clinical 
Practice guidelines. 
The primary endpoint of the study was the 6mPFS. Secondary end points included: PFS; overall 
survival (OS); overall response rate (ORR), defined as complete responses (CRs) + partial 
responses (PRs) + Minor Responses (MRs) (shrinkage of less than 30% but more than 10% in sum 
of the widest diameter of the lesions); disease control rate [DCR = ORR + stable diseases (SDs)]; 
duration of response (DOR); pain improvement, and safety. On paraffin-embedded tumor 
specimens immunohistochemical expression of P-ERK1/2 and P-RPS6 was correlated with 
outcome and scored as follows: <10% positive cells: 0+, 10-50% positive cells:1+; >50% positive 




PFS was calculated from study entry until progression, unacceptable toxicity or death whichever 
came first. OS was calculated from study entry until death. DOR was calculated from first non-
progression assessment until either progression/death. In absence of the event or loss to follow-up, 
all survival endpoints were censored at the last date the patient was known to be event-free. Any 
sign of tumor-related pain improvement was evaluated by means of the Pain and Analgesic Score 
(PAS)
27
 and the Brief Pain Inventory (BPI)
28
 form filled in autonomously by the patients.  
Chest and abdomen Computed Tomography (CT) and/or Magnetic Resonance Imaging (MRI) were 
performed at baseline, repeated every 2 months and anticipated if clinically indicated. CRs, PRs and 
MRs needed confirmation after at least 4 weeks. 
18
FDG-PET was suggested but not mandatory and 
was performed at baseline, during the third week of treatment and then if clinically indicated. Its 
impact on tumor response assessment was purely exploratory. 
 
Statistical analysis 
This was a non-randomized, multicenter, open-label phase II trial (NCT01804374). We used 
Simon's optimum two-stage design
29
 with 6mPFS as the primary end point. Patients alive and free 
from progression after 6 months were considered as successes.  
Based on our previous study with sorafenib alone, the trial was designed to rule out a 6mPFS of 
25% (null hypothesis) and target a 6mPFS of 50% (alternative hypothesis). Setting α-error at 0.05 
and β-error at 0.·10, in presence of at least six successes observed within the 17 patients enrolled in 
the first stage, the trial was allowed to proceed to the second stage in which 20 more patients 
needed to be enrolled, for a total of  at least 37 patients .  
In presence of 14 or more successes the experimental treatment could be considered worth further 
studies. The intention-to-treat analysis included all patients who received at least one pill of each 
drug. The efficacy analyzable population included all patients for whom a disease evaluation (either 
clinical or radiological) was performed. Survival endpoints were estimated according to the Kaplan 




were calculated and reported with their 95% CIs. The impact of P-ERK1/2 and P-RPS6K 
expression was evaluated by comparing survival outcomes using the two-sided Mantle-Cox log-
rank test, Fisher's exact test, and Mantel-Haenszel Odds Ratio (OR) estimate. Baseline vs. on-
treatment PAS and BPI scores were compared using paired student’s t test. All statistics were 
computed using IBM SPSS Statistics v.20 and GraphPad Prism v.5. 
 
Role of the funding source 
The Italian Sarcoma Group sponsored the trial through an unrestricted grant by Bayer and Novartis. 
Pharmaceutical companies had no role in data collection and interpretation, or writing of the report. 
All authors had access to the data, vouch for the completeness and accuracy of the data and analyses 
and approved the final version of the manuscript. The corresponding author (GG) had final 
responsibility for the decision to submit for publication. 
 
Results 
Patient characteristics  
From June 2011 and June 2013, 38 patients affected by relapsed and inoperable HG-OS were 
enrolled at three Italian Sarcoma Group centers. Table 1 describes patients’ baseline characteristics. 
All patients had already received MAP/I chemotherapy and the median number of previous 
systemic regimens was two (range one to three). All patients were treated according to the protocol 
and included in the safety and efficacy analyses. All analyses were performed after the last patient 
had been followed for at least 6 months. 
Safety 
The median follow up for safety analyses was 6 months (95% CI: 2-9). At last follow-up no patient 




9% were grade 3-4. All AEs occurring in at least one patient are listed in Table 2. The most 
common grade 3-4 AEs were lymphopenia in six (16%), hypophosphatemia in six (16%), hand and 
foot syndrome in five (13%), thrombocytopenia in four (11%), fatigue, oral mucositis, diarrhea and 
anemia in two (5%) of the patients. All of these AEs were causally related to the study drugs. One 
patient (3%) experienced a pneumothorax which required a trans-thoracic drainage (G3 according 
to CTCAE) and recurred at the time of PD. In both cases it was regarded as a Serious Adverse 
Event (SAE) related to the study drugs. No other SAEs were reported during the whole study. No 
death was related to the experimental treatment and all deaths were attributed to disease 
progression.  
Study drugs needed to be reduced or temporarily suspended in 25 (66%) patients because of toxicity 
(for details see table 3). In general, short drug interruptions were deemed useful in 22 (58%) 
patients to recover from toxicity and occurred more commonly during the first month of treatment 
than later on. The administered doses of sorafenib and everolimus were 77% (95% CI: 69-84%) and 
82% (95% CI: 75-89%) of the expected ones, respectively. The mean durations of temporary 
interruptions were 7 days (95% CI 5-9) and 7 days (95% CI 5-8) for sorafenib and everolimus, 
respectively (Table 3).   
Efficacy 
Progression in 34 (89%), toxicity in two (5%), lost to follow-up during treatment in one (3%) and 
lung metastasectomy in one (3%) patients were reasons to stop the experimental treatment. Eight 
patients (21%) received sorafenib and everolimus for more than eight months (8, 8, 9, 10, 10+, 11, 
11, 12 months, respectively). Within the 17 patients enrolled in the first stage we observed nine 
(53%, 95% CI: 26-79%) successes. According to the intention-to-treat analysis, of the 38 patients 
enrolled, 17 (45%, 95% CI: 28-61) were progression-free at 6 months (Figure 1). The median PFS 




patients surviving was 10 months (range 6-14). The median OS was 11 months (95% CI: 8-15) with 
a 12- and 24-month survival rate of 37% (95% CI: 21-53) and 5% (95% CI: 0-13%), respectively.  
We observed 2 (5%) PRs and 2 (5%) MRs for an ORR of 10% (Figure 2). Twenty (53%) patients 
achieved a SD and 14 (37%) had a progression. The DCR was 63% (95% CI: 47-79%). The median 
duration of treatment was 5 months (95% CI: 2-7). No CR was observed. On the contrary, we 
recorded 10 (33%) non-dimensional responses by means of 
18
FDG-PET in the 30 patients who 
underwent a PET-scan (mean 52% reduction in SUV within responding patients). One patient 
underwent lung metastasectomy after 10 months of disease control with stable disease according to 
RECIST criteria.  
We track and recorded self-perceived improvement. Pain improvement was not observed in terms 
of PAS score reduction (mean baseline: 1.9; mean best on treatment: 1·8, p=0·619), but a strong 
improvement was observed in 22 patients fully evaluable for BPI questionnaire (mean baseline 
score: 36 points; mean best on treatments score: 24, p=0·004). 
Biomarkers 
Immunohistochemical expression of P-ERK1/2 and P-RPS6 was fully evaluable in 33 (87%) and 35 
(92%) patients, respectively. We could not perform high-quality immunohistochemistry in 5 (P-
ERK1/2) and 3 (P-RPS6) HG-OS samples because of technical problem likely due to prolonged 
decalcification that impaired sample antigenicity. P-ERK1/2 staining was positive in 20 (61%) of 
the specimens and was significantly correlated with a better 6mPFS (OR 5, 95% CI: 1·04-24·03), p 
= 0·045). P-RPS6 staining (score 2+) was positive in 17 (49%) of the specimens and was associated 
with a better 6mPFS (61% vs 0%, p=0·008; OR not assessable), p<0·001). P-ERK1/2 and P-RPS6 
expression were both positive in 17 (51%) patients and predicted a better median PFS (7 vs. 2 






In HG-OS preclinical data had shown that the inhibition of mTOR pathway by means of 
everolimus
19
 might increase the activity of sorafenib.  We assessed this hypothesis studying the 
combination of sorafenib and everolimus in patients affected by inoperable HG-OS progressing 
after standard multidisciplinary treatment. Taking into consideration our previous study achieving a 
29% 6mPFS with sorafenib alone
18
, as primary endpoint, we deliberately set a high PFS rate of 
50% at a reasonably prolong time-point of 6 months. Regrettably, the present trial has not met the 
pre-specified threshold of activity to consider sorafenib and everolimus combination worth further 
phase III study.  Nevertheless, in the grim context of unresectable/relapsed HG-OS, our 6-month 
progression-free rate of 45% compares very favorably with former published studies addressing 
cohorts of patients with similar clinical characteristics (table ???). Moreover, this result stands 
clearly above the widely accepted 3- and 6mPFS of 40% and 20%, respectively
27
, to consider active 
a drug.
31
  In addition, Leary and Colleagues reported a median PFS of 1.8 months with a 6mPFS of 
less than 10% in pediatric patients affected by relapsed HG-OS who failed to achieve a second 
CR.
32 




To assess the activity of target therapies is always challenging and even more so in osteosarcoma in 
which either calcification or necrosis can occur in absence of tumor shrinkage.
18
 It could easily be 
argued that the observed ORR of 10% was unsatisfactory.  However, this is consistent with the 
ORR observed in other tumors with target therapies.
34
 Furthermore, it is well known that the correct 
response evaluation of bone lesions is always demanding in any tumor.
26
 Therefore, to improve our 
capability to interpreter imaging findings, we performed also 
18
FDG-PET. As in the example 
reported in figure 4, in a dimensionally stable disease the 
18
FDG uptake reduction was a further 
signal of study drugs anti-tumor activity. Moreover, since all enrolled patients had confirmed 




“dormancy”. To further detail this aspect, we show the progression-free survival of the whole 
cohort of patients during the therapy received before study enrollment (either surgery, 
chemotherapy or radiotherapy) and we found a median PFS of 2 months (CI95%: 2-3). (Figure 5). 
Indeed, in an unquestionably aggressive disease, 8 (21%) patients had an interesting tumor arrest 
lasting more than 8 months. Taken altogether these data support the concept of drugs affecting both 
tumor biology and progression. 
The reported AEs are consistent with those described in phase I trials. Notwithstanding, our 
younger cohort tolerated this combination slightly better than what is reported in previous 
experiences
23-25
. In synthesis, toxicity was relevant, but manageable in most cases. Of course, 
different drug dosages and clinical settings explain some of the observed differences. In general, 
drug related AEs were very common and required close contact between clinicians and patients to 
improve their best management. In fact, we had foreseen some enhancement of toxicity due to 
sorafenib and everolimus overlap on skin toxicity, stomatitis, thrombocytopenia and fatigue. 
Consequently, short interruptions as well as drug dose modulations were very helpful to permit drug 
re-introduction and prolonged use in responsive patients. 
There is a strong rational to combine a multikinase inhibitor (hitting tyrosine kinase receptors as 
PDGFR, VEGFR as well as ERK1/2)
35
 with a selective inhibitor of mTOR
19,36
 . This prompted us 
to explore the clinical validity of phosphorylated-ERK1/2 and -RPS6 as predictive biomarkers of 
sorafenib and everolimus combination activity. Our results support the concept to assess P-ERK1/2 
and P-RPS6 because their expression was associated with a statistically significant improved 
activity of the combination. Acknowledging the absence of a control group, our data are consistent 
with the predictive role of both P-ERK1/2 and P-RPS6 in renal and hepatic cancers.
37
 Moreover, the 
present data support the analytic validity of these biomarkers which had been previously studied by 
several groups on different series.
13-15,18
 Therefore, these biomarkers might be helpful to further 




The major limitation of this study is the lack of a control group to compare the results. We 
conceived this trial in order to quickly gather enough information on whether preclinical results on 
sorafenib and everolimus could be translated into the clinical scenario. In a rare tumor a randomized 
design would have required longer time to complete the study. We tried to strengthen the results by 
choosing objective and easily assessable endpoints at a reasonably distant time-point so as to 
minimize on one hand “Hawthorne effect”
38
 and, on the other hand, to generate clinical useful 
information on this combination activity. The challenge of studying the young population of 
relapsed and inoperable HG-OS in a randomized fashion is certified by the complete lack of 
randomized trial in the same setting. 
In conclusion, despite the fact that sorafenib and everolimus showed some degree of activity in 
relapsed and inoperable HG-OS, this combination did not significantly affect its dismal prognosis 
(no CR and only 1 patient made eligible to surgery). Awaiting significant advancement in the 
knowledge on osteosarcoma biology or innovative chemotherapy, any further study targeting these 
pathways should select the experimental population on the basis of the proposed biomarkers. In a 
subset of patients affected by tumor expressing P-ERK1/2 and/or P-RPS6, this experimental 
combination might be worth further prospective controlled clinical trials. 
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 N°  %  
Patients  38  100%  
Age (years) 
  - median (range) 
 
31 (18-64)   
Sex 
  - male 







Metastatic at diagnosis 
  - yes 







ECOG PS at start 
  - 0 
  - 1 









Lines of chemotherapy after 
MAP  
  = 1 



























Sites of metastases 
-  Lung only 
-  Lung + bone or viscera 









Table 1. Demographics and baseline characteristics. MAP, Methotrexate Adriamycin Cisplatin; 
ECOG PS, Eastern Cooperative Oncology Group Performance Status. *Patients with EOCG PS 2 










































































































































































































headache  2 5%  2 5%  0 0%  0 0%  0 0% 





































































value  95% CI  
Patients  38  100%  
Sorafenib dose (administered/expected) 77% 69-84% 
Everolimus dose (administered/expected) 82% 75-89% 
Treatment permanent interruption because of toxicity 
 - n of patients  







Treatment dose reduced/temporary interrupted 
  - n of patients  







Treatment temporary interrupted 
  - n of patients  







Dose levels sorafenib used 
 800 mg per day, n° (%) 
 600 mg per day (-1 dose level), n° (%) 









Days of interruption of sorafenib for single interruption 
   - mean 





Days of interruption of sorafenib during whole study 
   - mean 






Dose levels everolimus used 
 5 mg per day, n° (%) 
 2.5 mg per day (-1 dose level), n° (%) 







Days of interruption of everolimus for single interruption 
   - mean 





Days of interruption of everolimus during whole study 
  -  mean 





Table 3. Dose Reductions. *Six (16%) of the 19 (50%) patients who reduced sorafenib to 400 mg 
were also temporary treated at an intermediate dose level of 600 mg per day (-1 dose level). 
Thrombocytopenia (9 patients, 24%), hand and foot syndrome or other skin toxicities (7 patients, 
18%), hypertension and diarrhea (2 patients each, 5%) were the most common causes for sorafenib 




because of thrombocytopenia. Causes for temporary interruptions were: skin toxicity in 13 cases (10 
patients stopped both drugs, 2 sorafenib only, 1 everolimus only); thrombocytopenia in 10 cases (8 
both drugs, 2 everolimus only); diarrhea in 2 cases (1 both drugs, 1 sorafenib only); hypertension in 
2 cases (both drugs); pneumothorax in 2 cases in the same patient (both drugs); creatinine increase, 

























P-RPS6 1+ P-RPS6 2+ 




Figure 3. Immunohistochemical scores for P-ERK1/2 and P-RPS6. 0+ <10% positive cells; 1+ 10-
50% positive cells; 2+ >50% positive cells and high staining intensity (Panel A).  
Progression-free Survival curves for P-ERK1/2 positive and P-RPS6 2+ positive patients vs. 






Figure 4. PET response after 2 months of therapy. On the left PET scan performed at baseline; on 










Figure 5. Progression-free Survival of last treatment (either chemotherapy, radiotherapy or surgery) 
performed before study enrollment vs. the one obtained with sorafenib + everolimus 
 
